Georgetown University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Georgetown University sits in the top decile of US sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count).
Georgetown University: 227 sponsored US clinical trials, 34 recruiting.
Georgetown University sponsors 227 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 130 completed. 27 of these trials are in Phase 3-4 (later-stage) and 98 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 5 trials.
Top-decile sponsor footprint
Georgetown University ranks in the top decile of sponsors by registered trial count (#144 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
130 of 174 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (74.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
227 total, page 1 of 5
Home-based Vision Rehabilitation Guided by Brain Imaging
NCT07635329
Bundled Cancer Screening and Genetic Services Navigation
NCT07228000
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement
NCT06449313
Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors
NCT07128927
Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients
NCT06853925
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
NCT06980103
Visual Plasticity Following Brain Lesions
NCT07105358
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
NCT06892275
Mindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
NCT07028216
Post-Procedural Manual Manipulation for Infant Ankyloglossia
NCT06830148
Does Social Media Impact Adolescent Mental Health?
NCT06049888
F.L.O.S.S. Project (Facilitated Lessons on Oral and Systemic Health in Survivors)
NCT06315855
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
NCT06248515
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
NCT04675476
Tobacco Education and Lung Health Study (TEAL)
NCT06290869
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
NCT06015724
Connect to Baby: A Pilot Study of a Parenting and Coparenting Program
NCT06179576
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
NCT05256745
Phase IB/II of CPX-351 for Relapse Prevention in AML
NCT04990102
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
NCT05661201
Evaluating Novel Therapies in ctDNA Positive GI Cancers
NCT05482516
ReadMap: Reading in Stroke Alexia and Typical Aging
NCT06700005
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
NCT04865887
Mindful Self-Compassion for Anxiety Disorders and Depression
NCT05671419
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
NCT05130606
Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome
NCT05012475
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
NCT04499053
Improving Genetic Counseling for BRCA+ Mothers
NCT04258280
K0706 for Patients Diagnosed With Dementia With Lewy Bodies
NCT03996460
De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers
NCT06554158
Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy
NCT06902623
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies
NCT04002674
Older Breast Cancer Patients: Risk for Cognitive Decline
NCT03451383
DC Longitudinal Study on Aging and Specimen Bank
NCT03702907
Technology-supported Motor Rehabilitation for People With Rett Syndrome
NCT07418905
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
NCT06227546
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
NCT05827055
Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV
NCT05896852
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT05558982
A Multilevel Intervention to Improve Adherence to Childhood Cancer Survivorship
NCT05448560
Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis
NCT05551858
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
NCT04958811
Peer Support For Young Adult Women With High Breast Cancer Risk
NCT04248257
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
NCT04091750
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
NCT04005339
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
NCT03964532
Brain-based Understanding of Individual Language Differences After Stroke
NCT04991519
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
NCT03467867
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
NCT02985125
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
NCT05479045
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 43 |
| Phase 2 | 55 |
| Phase 3 | 16 |
| Phase 4 | 11 |
Therapeutic Areas
What is open in the Georgetown University pipeline
34 recruiting of 227 indexed (15% open); 130 completed (57%).
Phase mix: 27 late (III/IV) vs 98 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Georgetown University: open-pipeline peers nationwide
Peers matched on 227 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Georgetown University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 227 trials (± recruiting share)
- University of Iowa · 228 trials · 12% recruiting
- University Hospitals Cleveland Medical Center · 230 trials · 18% recruiting
- Brown University · 231 trials · 15% recruiting
- National Eye Institute (NEI) · 221 trials · 8% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Arizona State University · 15% recruiting · 187 trials
- 59th Medical Wing · 15% recruiting · 20 trials
- Alliance Foundation Trials · 15% recruiting · 20 trials
- Hoag Memorial Hospital Presbyterian · 15% recruiting · 20 trials
Related
What to do with this Georgetown University page
227 registered trials is a research-attention snapshot, not an endorsement of Georgetown University or any single study.
- 34 of Georgetown University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Georgetown University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Georgetown University pipeline card: 227 registered trials from official public datasets.Report a data error.